Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 693 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Dermatitis Clear all
Completed Phase 3 Interventional Results available

Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT02277743
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Dupilumab, Placebo (for Dupilumab)
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
45
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional

The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment

NCT04358224
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Dupilumab Prefilled Syringe
Biological
Lead sponsor
Jonathan A. Bernstein, MD
Other
Eligibility
19 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

NCT03496974
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Bermekimab Monoclonal Antibody 200 mg, Bermekimab Monoclonal Antibody 400 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis

NCT00120523
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Topical corticosteroids
Drug
Lead sponsor
MEDA Pharma GmbH & Co. KG
Industry
Eligibility
3 Months to 12 Months
Enrollment
2,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 21, 2026, 7:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Cathelicidin Expression in Skin and Saliva in Patients With Atopic Dermatitis and Psoriasis

NCT00407979
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
2
States / cities
San Diego, California • Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis

NCT06921759
View directory record Official record
Conditions
Atopic Hand and Foot Dermatitis
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Fountain Valley, California • Los Angeles, California • Hollywood, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT03720470
View directory record Official record
Conditions
Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Dupilumab, Oral Placebo, Injectable Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
60
States / cities
Birmingham, Alabama • Huntington Beach, California • Laguna Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

NCT02655679
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P
Drug · Other
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional Results available

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016
View directory record Official record
Conditions
Asthma, Allergic Rhinitis, Atopic Dermatitis
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Clinical Evaluation of Skin Microbiome an Over-The-Counter (OTC) Drug for Atopic Dermatitis

NCT07146971
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
OTC Drug for Atopic Dermatitis in Cream form
Drug
Lead sponsor
Good Molecules, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Results available

Acupressure in Pruritus for Atopic Dermatitis

NCT01074164
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Standard-of-care treatment for AD, Accu-patch pellet
Other · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 2 Interventional Results available

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05999799
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
GSK1070806, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Canoga Park, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

NCT02595073
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 21, 2026, 7:22 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT05735483
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Lebrikizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Months to 18 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
21
States / cities
Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Community-based Assessment of Skin Care, Allergies, and Eczema

NCT03409367
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Disorders, Eczema, Atopic Eczema
Interventions
Participant choice of over-the-counter emollients: Vaseline, Vanicream, CeraVe Healing Ointment, CeraVe cream, Cetaphil cream
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
1 Day to 63 Days
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
4
States / cities
Denver, Colorado • Durham, North Carolina • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 21, 2026, 7:22 PM EDT
Withdrawn Phase 2 Interventional

Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone

NCT04325802
View directory record Official record
Conditions
Atopic Dermatitis, Pruritus, Pruritus Chronic, Dermatitis
Interventions
Naltrexone, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 21, 2026, 7:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

NAET Screening for Food Allergy, Sensitivity and Intolerances Using IgE-Specific Antigen Test and NST- NAET®

NCT00275795
View directory record Official record
Conditions
Food Sensitivities, Headache, Backache, Indigestion, Eczema, Acne, Hives and Itching of the Skin
Interventions
NAET Procedures
Procedure
Lead sponsor
Nambudripad's Allergy Research Foundation
Other
Eligibility
2 Years to 78 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Buena Park, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2006 · Synced Oct 21, 2026, 7:22 PM EDT
Terminated Phase 3 Interventional

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

NCT00176956
View directory record Official record
Conditions
Dermatitis
Interventions
Skin Biopsy
Procedure
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
Up to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2013 · Synced Oct 21, 2026, 7:22 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease

NCT07487831
View directory record Official record
Conditions
Atopic Dermatitis (Eczema), Psoriasis
Interventions
Sodium chloride tablets, Placebo Tablets
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional

A Comparison Study Between Protopic (Tacrolimus) Ointment and Elidel (Pimecrolimus) Cream in Treating Subjects With Atopic Dermatitis

NCT00666302
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
tacrolimus ointment, pimecrolimus cream
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
16 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
13
States / cities
Birmingham, Alabama • San Francisco, California • Kansas City, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 2 Interventional Results available

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

NCT02683928
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GBR 830, Placebo
Biological
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

NCT07006792
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 7:22 PM EDT
Completed Phase 4 Interventional

Epiceram Versus Elidel for Treatment of Mild to Moderate Atopic Dermatitis

NCT00460083
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Elidel(R) (pimecrolimus 1%), EpiCeram(R) -ceramide based barrier repair cream
Drug · Device
Lead sponsor
Ceragenix Pharmaceuticals
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
San Diego, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 6, 2008 · Synced Oct 21, 2026, 7:22 PM EDT